GI Oncology Daily Digest

April 23, 2026 — Post-AACR 2026 Edition
Curated by Dr. Allan Pereira — Moffitt Cancer Center

Top 5 Papers

#1
Zolbetuximab + mFOLFOX6 + Nivolumab: Triplet Achieves mPFS 18.0 Months in CLDN18.2-High Gastric Cancer (Nature Medicine)
Source: Nature Medicine / ILUSTRO Phase 2  |  Authors: Shitara K et al.  |  Published: April 2026
Score: 12/20 — Nature Medicine (9) + Phase 2 randomized data (+2) + novel CLDN18.2 + IO + chemo triplet (+1)
The ILUSTRO Phase 2 trial (cohort 4B, n=71) evaluated first-line zolbetuximab (anti-CLDN18.2) combined with mFOLFOX6 and nivolumab in CLDN18.2-positive, HER2-negative metastatic gastric or gastroesophageal junction adenocarcinoma, published in Nature Medicine. At median follow-up of 11.5 months, overall median PFS was 14.8 months (95% CI 8.3–NE) with 12-month PFS rate of 59.1%. In CLDN18.2-high patients (n=59), median PFS reached 18.0 months with 12-month PFS of 64.2%. The combination was well-tolerated. These results support the rationale for combining CLDN18.2 targeting with immune checkpoint inhibition and chemotherapy, and a Phase 3 trial is planned. Lead author Kohei Shitara noted particular benefit in PD-L1 CPS ≥1 patients.
Post angle: Nature Medicine: Zolbetuximab + FOLFOX + nivolumab in CLDN18.2+ gastric cancer. mPFS 18.0 mo in CLDN18.2-high pts (64% at 12 mo). CLDN18.2 + IO + chemo triplet. Phase 3 coming. #GastricCancer #CLDN182 #PrecisionMedicine
#2
Givastomig (CLDN18.2 x 4-1BB Bispecific): ORR 77%, mPFS 16.9 Months in 1L Gastric Cancer; FDA Accelerated Approval Pathway Confirmed
Source: FDA / NovaBridge Biosciences  |  Authors: NovaBridge Biosciences  |  Published: March–April 2026
Score: 11/20 — FDA accelerated pathway (8) + Phase 1b ORR 77% (+2) + novel CLDN18.2 x 4-1BB mechanism (+1)
NovaBridge Biosciences reported Phase 1b dose-expansion data for givastomig, a first-in-class CLDN18.2 x 4-1BB bispecific antibody, combined with immunochemotherapy in first-line CLDN18.2-positive, HER2-negative, PD-L1-positive metastatic gastric cancer. Among 52 efficacy-evaluable patients, ORR was 77% at the 8 mg/kg dose with median PFS of 16.9 months and 6-month PFS rate of 82%. The FDA confirmed eligibility for an accelerated approval pathway in a productive Type B meeting (March 2026). A registrational Phase 3 trial is planned for Q4 2026 with ORR as primary endpoint. The CLDN18.2 x 4-1BB mechanism provides dual tumor targeting and T-cell costimulation, differentiating from standard anti-CLDN18.2 approaches.
Post angle: Givastomig: CLDN18.2 x 4-1BB bispecific in 1L gastric cancer. • ORR 77% at 8 mg/kg • mPFS 16.9 months • FDA: accelerated approval pathway confirmed • Phase 3 planned Q4 2026 CLDN18.2 targeting gets a new dimension — dual tumor targeting + T-cell costimulation. #GastricCancer #CLDN182
#3
Lancet Commission on Addressing the Global Hepatocellular Carcinoma Burden: From Prevention to Treatment
Source: The Lancet / Global HCC Commission  |  Authors: Lancet HCC Commission  |  Published: April 2026
Score: 10/20 — Lancet (9) + comprehensive global framework (+1)
The Lancet Commission on hepatocellular carcinoma presents a comprehensive global framework addressing the entire HCC continuum from prevention through treatment. The Commission outlines strategies including: universal HBV vaccination scale-up, HCV elimination through direct-acting antivirals, MASLD/MASH screening in high-risk metabolic populations, HCC surveillance optimization with biomarker-enhanced protocols, and treatment algorithm updates incorporating recent systemic therapy advances (atezo/bev, durvalumab/tremelimumab, TACE combinations). The Commission emphasizes the shifting epidemiology of HCC, with MASLD/MASH now surpassing viral hepatitis as the leading etiology in Western countries, and calls for integrated care pathways across hepatology and oncology.
Post angle: The Lancet Commission on HCC: comprehensive global framework. • MASLD/MASH now leading HCC cause in the West • HBV/HCV elimination strategies • Biomarker-enhanced surveillance • Updated systemic therapy algorithms Prevention → screening → treatment. The full continuum. #HCC #LiverCancer #Lancet
#4
Amivantamab + Chemotherapy Shows Durable First-Line Responses in RAS/BRAF Wild-Type Metastatic CRC (OrigAMI-1 Updated)
Source: ASCO GI 2026 / Johnson & Johnson  |  Authors: Arnold D et al.  |  Published: January 2026 (updated April 2026)
Score: 9/20 — ASCO GI presentation (6) + durable 1L responses (+2) + novel EGFR-MET bispecific in CRC (+1)
Updated longer-term results from the OrigAMI-1 Phase 1b/2 study of amivantamab (EGFR-MET bispecific antibody) combined with FOLFOX or FOLFIRI chemotherapy in RAS/BRAF wild-type metastatic colorectal cancer showed promising and durable first-line responses with low treatment discontinuation rates. Amivantamab provides simultaneous EGFR and MET pathway blockade with immune cell-directing activity, offering a differentiated mechanism from standard anti-EGFR monoclonal antibodies (cetuximab, panitumumab). The Phase 3 OrigAMI-3 trial is being planned to evaluate amivantamab combinations in frontline mCRC. This bispecific approach may overcome resistance mechanisms seen with conventional anti-EGFR therapy.
Post angle: Amivantamab + chemo in RAS/BRAF WT mCRC (OrigAMI-1 updated). EGFR-MET bispecific + FOLFOX/FOLFIRI in first line: • Durable responses, low discontinuation • Dual EGFR + MET blockade + immune cell-directing • Phase 3 OrigAMI-3 planned Beyond cetuximab/panitumumab. #CRC #EGFR #Bispecific
#5
Pelareorep + Bevacizumab + FOLFIRI Receives FDA Fast Track for KRAS-Mutated MSS Metastatic CRC (2L)
Source: FDA Fast Track Designation  |  Authors: Oncolytics Biotech  |  Published: 2026
Score: 8/20 — FDA Fast Track (6) + MSS CRC unmet need (+1) + novel IO combo in KRAS-mut (+1)
The FDA granted Fast Track Designation to pelareorep, an oncolytic reovirus immunotherapy, in combination with bevacizumab and FOLFIRI for second-line treatment of patients with KRAS-mutated, microsatellite-stable (MSS) metastatic colorectal cancer. MSS mCRC represents approximately 85% of mCRC and has been largely unresponsive to immune checkpoint inhibitors. KRAS-mutated MSS mCRC has particularly limited options after first-line progression. Pelareorep selectively replicates in RAS-activated tumor cells, potentially converting immunologically cold tumors into hot targets. This designation accelerates the regulatory path for a population with critical unmet need.
Post angle: Pelareorep + bev + FOLFIRI: FDA Fast Track for KRAS-mutated MSS mCRC (2L). • Oncolytic reovirus selectively targets RAS-activated cells • May convert “cold” MSS tumors to “hot” • ~85% of mCRC is MSS, KRAS-mut is the hardest subset Another approach tackling the MSS CRC problem. #CRC #MSS #Immunotherapy

Additional Papers of Interest

  1. TCX-201 Achieves Complete Tumor Regressions in CRC and PDAC Preclinical Models (AACR 2026)
    AACR 2026 — TCX-201 candidate delivers complete tumor regressions in colorectal and pancreatic cancer preclinical models, representing a novel therapeutic approach.
  2. Encorafenib + Cetuximab + mFOLFOX6 Converts to Traditional FDA Approval for 1L BRAF V600E mCRC (BREAKWATER)
    FDA — BREAKWATER regimen receives traditional (full) approval for first-line BRAF V600E mCRC, converting from prior accelerated approval.
  3. Gut Microbiota Influences Chronic Sleep Deprivation-Induced CRC Progression (AACR 2026)
    AACR 2026 — Translational research demonstrates gut microbiome-mediated mechanisms linking chronic sleep deprivation to CRC progression and treatment response.
  4. DYNAMIC 5-Year Follow-Up: ctDNA-Guided Adjuvant Therapy in Stage II Colon Cancer (Nature Medicine)
    Nature Medicine — Five-year outcomes of the landmark DYNAMIC trial confirm long-term benefit of ctDNA-guided adjuvant therapy decisions in stage II colon cancer.
  5. OrigAMI-3 Phase 3 Trial Planned: Amivantamab in Frontline Metastatic Colorectal Cancer
    Targeted Oncology — Phase 3 OrigAMI-3 will evaluate amivantamab-based combinations in first-line mCRC, building on Phase 1b/2 durable response data.
  6. CLDN18.2 Targeting in Gastric Cancer: Review of Emerging Biologic Agents (2026)
    Expert Opinion on Biological Therapy (2026) — Comprehensive review of zolbetuximab, givastomig, and next-gen CLDN18.2 agents reshaping the gastric cancer landscape.
Back to all digests